Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565992 · ClinicalTrials.gov registry record · Phase 1
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
A Phase 1 study of Melanoma, sponsored by Viralytics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT02565992 is a Phase 1 study of Melanoma that has completed, run by Viralytics. The registered enrollment target is 36 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02565992, a Phase 1 study of Melanoma, has completed, sponsored by Viralytics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will employ a phase Ib design using the established dose of CAVATAK with pembrolizumab in subjects with advanced melanoma for whom pembrolizumab would be considered standard of care. Our hypothesis is that oncolysis of melanoma cells by CAVATAK will be important in amplifying the T-cell potentiating effects of pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL CAVATAK
Study Locations (3)
California
- John Wayne Cancer Institute - Santa Monica
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Ohio
- Gabrail Cancer Center Research - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-12-17 |
| Est. Completion | 2019-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02565992
The ClinicalTrials.gov registry entry for NCT02565992 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The listed sponsor is Viralytics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02565992 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, New Jersey, Ohio.
Frequently Asked Questions
What is clinical trial NCT02565992 about?
NCT02565992 is a clinical study titled "Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)". This study will employ a phase Ib design using the established dose of CAVATAK with pembrolizumab in subjects with advanced melanoma for whom pembrolizumab would be considered standard of care. Our hypothesis is that oncolysis of melanoma cells by CAVATAK will be important in amplifying the T-cell p...
What is the current status of trial NCT02565992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-12-17. Estimated completion is 2019-11-04.
What conditions does trial NCT02565992 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02565992?
The interventions under investigation include: Pembrolizumab (DRUG), CAVATAK (BIOLOGICAL).
Who is sponsoring clinical trial NCT02565992?
This trial is sponsored by Viralytics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02565992 being conducted?
This trial has 3 study locations across California, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.